Last reviewed 2026-04-20 · How we verify

Shingrix (shingrix)

Shingrix is a marketed vaccine by GSK for preventing herpes zoster (shingles) in adults aged 50 years and older. It reduces the incidence of herpes zoster, a disease caused by reactivation of the varicella zoster virus. Shingles provokes a painful rash with blisters and can be followed by chronic pain and other complications. Older people are more often affected, as are people with weakened immune systems. Vaccination can prevent both shingles and postherpetic neuralgia. Shingrix has shown significant commercial success with $1.07B in revenue and a large number of trials and publications. Its mechanism is focused on reducing the incidence of herpes zoster.

At a glance

Approved indications

• Prevention of herpes zoster (shingles) in adults aged 50 years and older

Common side effects

• Pain
• Myalgia
• Fatigue
• Headache
• Redness
• Shivering
• Swelling
• Fever
• Gastrointestinal symptoms
• Pain Grade 3
• Myalgia Grade 3
• Fatigue Grade 3

Drug interactions

• Live, attenuated influenza vaccines
• Live vaccines
• Other vaccines
• Immunosuppressive therapies
• Interferon-alpha
• Interferon-gamma
• Corticosteroids
• Azathioprine
• Cyclophosphamide
• Cyclosporine
• Methotrexate
• Sirolimus

Key clinical trials

• Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients (PHASE4)
• A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
• Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
• Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies (NA)
• Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
• Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
• Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
• Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.